The Principals

Dr. Roger Hodkinson, MA, MB (Cambridge UK), FCAP, FRCPC

Executive Chairman

Dr. Hodkinson is a broadly experienced clinical pathologist who holds medical degrees from Cambridge University in the United Kingdom. Prior to his association with MutantDx, he was the CEO of Stirrat Laboratories, a large retail diagnostic medical laboratory in Alberta, Canada.  Dr. Hodkinson is a Past President of the Alberta Society of Laboratory Physicians (ASLP), which represents pathologists in Alberta, Canada, and was a key player in the restructuring of the $250M diagnostic laboratory industry in that Province.  He has acted as a laboratory accreditation inspector, and was previously Chairman of the Examination Committee in General Pathology for the Royal College of Physicians of Canada. He was previously a Fellow of the College of American Pathologists and has been the Medical Director of a CLIA laboratory. Dr. Hodkinson is a co-author of publications based on MultiGEN technology.

Dr T. Vinayagamoorthy (‘Moorthy’) Ph.D.

Founder and Chief Scientific Officer

Dr. Vinayagamoorthy (‘Dr. Moorthy’) holds a Ph.D. in microbiology, and his scientific career spans Sri Lanka, Sweden, Canada and the USA. He was previously the Head of the Departmentof Biochemistry, University of Jaffna, Sri Lanka, and has been a member of the editorial board of the Journal of Clinical Microbiology, USA.

Dr. Moorthy was the principal coordinator for one of the largest collaborative studies on the spread of community antibiotic resistance and incidence of high trimethoprim resistance. He was the principal discoverer of the melanoma-associated gene, Calnexin, of importance in understanding the skin malignancy melanoma. During his forty-year career, Dr. Moorthy has authored over 70 peer reviewed publications in various scientific journals and presented at many international scientific conferences. His publications include Oversight in Clinical Trial Protocols (Lancet Oncology) for the comparative assessment of molecular diagnostic tests.

Stimulated by the need for innovative molecular technologies that meet specific clinical expectations, Dr Moorthy invented and patented a number of platform technologies in molecular diagnostics related to infectious disease, cancer and other fields. He is the principal intellectual force behind the development of a portfolio of ten patented platform technologies used for MutantDx applications.

As a scientist/entrepreneur Dr Moorthy has founded biotech companies in Canada and the USA, sold a CLIA clinical laboratory, and out-licensed molecular diagnostics platform technologies to US companies.